Interv Akut Kardiol. 2017;16(3):113-115 | DOI: 10.36290/kar.2017.031

Very late thrombosis in bioresorbable scaffold

Juraj Bujdák1, Ivo Varvařovský2, Vojtěch Novotný2, Jan Matějka1, 2
1Kardiologické oddělení, Nemocnice Pardubického kraje, a. s., Pardubice
2Kardiologické centrum Agel, a. s., Pardubice

The authors report a case of very late thrombosis in a patient with a bioresorbable scaffold. In the discussion are considered possibleetiological factors of this event, the results of clinical trials and current recommendations for long-term antiplatelet therapy.

Keywords: PCI (percutaneous coronary intervention), bioresorbable vascular scaffold, very late thrombosis

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bujdák J, Varvařovský I, Novotný V, Matějka J. Very late thrombosis in bioresorbable scaffold. Interv Akut Kardiol. 2017;16(3):113-115. doi: 10.36290/kar.2017.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Testa L, Latib A, Montone RA, Colombo A, Bedogni F. Coronary Bioresorbable Vascular Scaff old Use in theTreatment of Coronary Artery Disease. Circ Cardiovasc Interv. 2016; 9(7). Go to original source... Go to PubMed...
    2. Novotný V, Varvařovský I, Matějka J, Rozsíval V, Lazarák T. Biodegradabilní stenty - kouzlo pomíjivého? Interv Akut Kardiol 2016; 15(3): 127-134. Go to original source...
    3. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaff olds: rationale, current status, challenges, and future. Eur Heart J. 2014; 35(12): 765-776. Go to original source... Go to PubMed...
    4. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaff olds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16-25b. Go to original source... Go to PubMed...
    5. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaff olds to metal platform coronary stents. JACC Cardiovasc Interv 2010; 3: 1190-1198. Go to original source... Go to PubMed...
    6. Okamura T, Serruys PW, Regar E. Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J 2010; 31: 2179. Go to original source... Go to PubMed...
    7. Wykrzykowska J, Kraak R, Hofma S, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med 2017; 376: 2319-2328. Go to original source... Go to PubMed...
    8. Serruys PW, et. al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial, Lancet Vol. 388 p 2479-2491. Go to original source... Go to PubMed...
    9. Stephen G, Ellis MD, Dean J, Kereiakes MD, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med 2015; 373: 1905-1915. Go to original source... Go to PubMed...
    10. Giacchi G, Ortega-Paz L, Brugaletta S, Ishida K, Sabaté M. Bioresorbable vascular scaff olds technology: current use and future developments. Med Devices (Auckl). 2016; 9: 185-198. Go to original source... Go to PubMed...
    11. Capodanno D, Angiolillo DJ. Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions. JACC Cardiovasc Interv. 2017; 10(5): 425-437. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.